6QSW

Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine.

This is a non-PDB format compatible entry.

Summary for 6QSW

• Entry DOI: 10.2210/pdb6qsw/pdb
• Descriptor: Complement factor B, SULFATE ION, ~{N}-(2-bromanyl-4-methyl-naphthalen-1-yl)-4,5-dihydro-1~{H}-imidazol-2-amine, ... (4 entities in total)
• Functional Keywords: complement, immune, inhibitor, c3 convertase, hydrolase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 3
• Total formula weight: 100740.83

Authors

Adams, C.M.,Sellner, H.,Ehara, T.,Mac Sweeney, A.,Crowley, M.,Anderson, K.,Karki, R.,Mainolfi, N.,Valeur, E.,Sirockin, F.,Gerhartz, B.,Erbel, P.,Hughes, N.,Smith, T.M.,Cumin, F.,Argikar, U.,Mogi, M.,Sedrani, R.,Wiesmann, C.,Jaffee, B.,Maibaum, J.,Flohr, S.,Harrison, R.,Eder, J. (deposition date: 2019-02-22, release date: 2019-03-27, Last modification date: 2024-01-24)

Primary citation

Schubart, A.,Anderson, K.,Mainolfi, N.,Sellner, H.,Ehara, T.,Adams, C.M.,Mac Sweeney, A.,Liao, S.M.,Crowley, M.,Littlewood-Evans, A.,Sarret, S.,Wieczorek, G.,Perrot, L.,Dubost, V.,Flandre, T.,Zhang, Y.,Smith, R.J.H.,Risitano, A.M.,Karki, R.G.,Zhang, C.,Valeur, E.,Sirockin, F.,Gerhartz, B.,Erbel, P.,Hughes, N.,Smith, T.M.,Cumin, F.,Argikar, U.A.,Haraldsson, B.,Mogi, M.,Sedrani, R.,Wiesmann, C.,Jaffee, B.,Maibaum, J.,Flohr, S.,Harrison, R.,Eder, J.
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Proc.Natl.Acad.Sci.USA, 116:7926-7931, 2019

PubMed Abstract: Dysregulation of the alternative complement pathway (AP) predisposes individuals to a number of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy. Moreover, glomerular Ig deposits can lead to complement-driven nephropathies. Here we describe the discovery of a highly potent, reversible, and selective small-molecule inhibitor of factor B, a serine protease that drives the central amplification loop of the AP. Oral administration of the inhibitor prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats. In addition, inhibition of factor B prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes. These data demonstrate the potential therapeutic value of using a factor B inhibitor for systemic treatment of complement-mediated diseases and provide a basis for its clinical development.

PubMed: 30926668
DOI: 10.1073/pnas.1820892116

Experimental method

X-RAY DIFFRACTION (1.64 Å)